Electronic decision aid for stroke prevention in atrial fibrillation
Official title: Pilot Clinical Trial of the Risk Assessment and Personal Preference to Improve Decisions in Atrial Fibrillation Patient Decision Aid for Stroke Prevention in Atrial Fibrillation: the RAPID AFib Pilot Trial.
Run by University of Calgary · NCT05900414 · Data updated 2026-11-12
This study is testing a new electronic tool to help people with atrial fibrillation make better choices about stroke prevention treatments before their doctor visits.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | University of Calgary Academic / other |
| Locations | 2 sites (Calgary, Alberta and 1 other locations) |
| Status | Recruiting |
| Started | April 1, 2024 |
| Main results expected | October 2025 |
| Study ends | October 2025 |
| Registry record updated | April 2, 2025 |
| Trial ID | NCT05900414 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 or older with a recent diagnosis of non-valvular atrial fibrillation and no prior anticoagulant treatment or treatment for less than 90 days.
✕Probably not a fit
Patients with valvular atrial fibrillation or those currently on dual antiplatelet therapy for reasons other than atrial fibrillation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot clinical trial evaluates a new electronic patient decision aid designed to enhance shared decision-making for stroke prevention in patients with atrial fibrillation. Participants, diagnosed with atrial fibrillation within the last year, will receive either standard educational materials or the decision aid alongside these materials before their specialist visit. The study aims to determine the acceptability of the decision aid and its effectiveness in improving decision quality compared to standard care. By facilitating better understanding and choices regarding anticoagulant therapy, the trial seeks to address gaps in stroke prevention strategies.
Why it matters
Potential benefit: If successful, this approach could significantly improve patient understanding and adherence to stroke prevention therapies, potentially reducing the incidence of AF-associated strokes.
How similar studies have gone: Other studies have shown promise in using patient decision aids for improving shared decision-making in various medical contexts, suggesting potential success for this novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Non-valvular AF diagnosed within 12 months, with any level of stroke risk assessed by CHA2DS2-VASc score. * Age 18 or older * Either no OAC treatment or treated for less than 90 days. * Initial specialist AF visit scheduled in 7-30 days. Exclusion Criteria: * Valvular AF, defined, per Canadian Cardiovascular Society Guidelines, as AF in the presence of mechanical heart valves, rheumatic mitral stenosis, or moderate to severe nonrheumatic mitral stenosis. * Currently prescribed dual antiplatelet therapy (ASA plus either clopidogrel, ticagrelor, or prasugrel) for an indication other than AF. * Has an independent, non-AF indication for oral anticoagulation. * Has a non-modifiable impediment to effective use of web-based tools. Examples include lack of internet access, lack of English literacy (Grade 5 level).
Where it's running
-
Calgary Zone, Alberta Health Services
Calgary, Alberta, Canada Recruiting -
Vita Diagnostics
Calgary, Alberta, Canada Recruiting
Study contacts
- Principal investigator: Stephen B Wilton, MD — University of Calgary
- Study coordinator: Stephen B Wilton, MD
- Email: sbwilton@ucalgary.ca
- Phone: 403-210-7102
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities
This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.
-
Dual Energy ablation with SmartTouch SF catheter in persistent atrial fibrillation
This study tests a pulsed field and radiofrequency ablation system to treat persistent atrial fibrillation in adults who have not responded well to prior medications.
-
Identifying AF patients who may need more than standard ablation using Volta AF-Xplorer II
This trial tests whether AI-identified dispersion areas during AF ablation can predict recurrence after a standard pulmonary vein isolation in patients with persistent AF.
-
4D intracardiac echocardiography to guide left atrial appendage occlusion procedures
A new 4D ICE catheter is being tested alongside standard imaging to see if it can safely guide left atrial appendage occlusion procedures for adults with atrial fibrillation.
-
Thoracoscopic vs Catheter Ablation as the First Rhythm Control in Atrial Fibrillation with a Large Left Atrium
This trial tests whether thoracoscopic surgical ablation is better at keeping atrial fibrillation under control than catheter ablation in people with persistent AF and a large left atrium who have not had an ablation before.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.